Email Alert RSS
Volume 13 Issue 6
Nov.  2022
Turn off MathJax
Article Contents
Article Navigation >  Medical Journal of Peking Union Medical College Hospital  > 2022  >  13(6): 1028-1035
CHEN Chen, HAN Xiaohong. Clinical Trials of Rare Diseases in China over One Decade: Based on the Chinese First List of Rare Diseases[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(6): 1028-1035. doi: 10.12290/xhyxzz.2022-0010
Citation: CHEN Chen, HAN Xiaohong. Clinical Trials of Rare Diseases in China over One Decade: Based on the Chinese First List of Rare Diseases[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(6): 1028-1035. doi: 10.12290/xhyxzz.2022-0010
shu

Clinical Trials of Rare Diseases in China over One Decade: Based on the Chinese First List of Rare Diseases

doi: 10.12290/xhyxzz.2022-0010
  • 1.

    Clinical Pharmacology Research Center, NMPA Key Laboratory for Clinical Research and Evaluation of Drug, Beijing Key Laboratory of Clinical PK & PD Investigation for Innovative Drugs, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China

  • 2.

    State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China

Funds:

China National Major Project for New Drug Innovation 2019ZX09201002

CAMS Innovation Fund for Medical Sciences CIFMS 2021-1-I2M-003

More Information
  • Corresponding author: HAN Xiaohong, E-mail: hanxiaohong@pumch.cn
  • Received Date: 2022-01-07
  • Accepted Date: 2022-04-01
    • Available Online: 2022-09-09
  • Publish Date: 2022-11-30
    Abstract
  •   Objective  To explore the situation and characteristics of clinical trials of 121 rare diseases in the Chinese First List of Rare Diseases over the past 10 years and to provide reference for promoting the researchand development of orphan drugs in China.  Methods  The 121 rare diseases covered in the Chinese First List of Rare Diseases and Guidelines for Diagnosis and Treatment of Rare Diseases published in 2019 were retrieved as keywords on the National Medical Products Administration Registration and Information Disclosure Platform for Drug Clinical Studies (chinadrugtrials.org.cn) from November 1st, 2012 (Platform registration open time) to November 28th, 2021. The status and characteristics of rare disease clinical trials were analyzed from the perspectives of the number of registrations, geographical distribution, research fields, research design, and sample size.  Results  A total of 235 clinical trials were collected, including 41 items of phase Ⅰ, 22 items of phase Ⅱ, 74 items of phase Ⅲ, 15 items of phase Ⅳ, 77 items of bioequivalence clinical trials, and 6 clinical trials. During the past 10 years, the number of rare diseases clinical trials in China showed an increasing trend, with an annual average growth rate of about 54%. A total of 16 kinds of rare diseases in the Chinese First List of Rare Diseases were involved in the early phase (phase Ⅰ and phase Ⅱ) clinical trials, mainly focusing on hemophilia, idiopathic pulmonary fibrosis, multiple sclerosis, and neuromyelitis optica. The researchers of rare disease clinical trials were mainly in big cities such as Beijing, Tianjin, and Shanghai. Phase Ⅰ clinical trials of rare diseases listed in the Chinese First List of Rare Diseases in China were mainly single-center(61%, 25/41) parallel controlled studies (46%, 19/41), Phase Ⅱ clinical trials were mainly multi-center parallel controlled studies (65%, 13/22), and phase Ⅲ clinical trials were mainly multi-center (99%, 73/74) single-arm trials (64%, 47/74). The sample size in clinical trials increased with the study stage. Phase Ⅰ clinical trials were mainly restricted to 11~50 cases (83%, 34/41), 59% (13/22) of phase Ⅱ clinical trials were more than 50 cases, and 53%(39/74) of phase Ⅲ clinical trials involved 51~500 cases.  Conclusions  The research and development of orphan drugs in China is still at an early stage, covering few rare diseases in the Chinese First List of Rare Diseases, but it has shown a rapidly growing trend in recent years. At present, the development of rare disease drugs is still based on traditional clinical trial design. It is therefore necessary to explore more new clinical research strategies according to the disease and drug mechanism to promote the development of rare disease drugs.
    • FullText(HTML)
  • loading
    • References(15)
  • [1] Ferreira CR. The burden of rare diseases[J]. Am J Med Genet A, 2019, 179: 885-892. doi:  10.1002/ajmg.a.61124
    [2] 国家卫生健康委员会, 科学技术部, 工业和信息化部, 等. 关于公布第一批罕见病目录的通知[EB/OL]. (2018-05-11)[2022-01-05]. http://www.gov.cn/zhengce/zhengceku/2018-12/31/content_5435167.htm.
    [3] Insight数据库. 罕见病综合报告[R/OL]. (2022-08)[2022-01-05]. https://db.dxy.cn/v5.
    [4] 白桦, 张抒扬. 有关促进国内罕见病药物临床试验的几点建议[J]. 国际药学研究杂志, 2019, 46: 679-684. https://www.cnki.com.cn/Article/CJFDTOTAL-GWYZ201909009.htm
    [5] 张越飞. 浅析当前我国罕见病相关政策法规[J]. 中国食品药品监管, 2020 (3): 26-30. https://www.cnki.com.cn/Article/CJFDTOTAL-YPJD202003006.htm
    [6] 周萍, 康怡, 张东肃, 等. 基于美国临床试验数据库的罕见病临床试验现状研究及启示[J]. 中国医院用药评价与分析, 2020, 20: 1134-1137. https://www.cnki.com.cn/Article/CJFDTOTAL-YYPF202009030.htm
    [7] 李丹. 美国罕见病药物研发激励政策概述及对我国的启示[J]. 中国药物警戒, 2018, 15: 339-342. https://www.cnki.com.cn/Article/CJFDTOTAL-YWJJ201806005.htm
    [8] 石鑫淼, 刘徽, 王琳, 等. 基于中国1500万余例次住院病例的121种罕见病现况分析[J]. 中华医学杂志, 2018, 98: 3274-3278.
    [9] Yang D, Ren X, Lu Y, et al. Current diagnosis and management of rare pediatric diseases in China[J]. Intractable Rare Dis Res, 2021, 10: 223-237.
    [10] Abrahamyan L, Feldman BM, Tomlinson G, et al. Alterna-tive designs for clinical trials in rare diseases[J]. Am J Med Genet C Semin Med Genet, 2016, 172: 313-331.
    [11] 国家药品监督管理局药品审评中心. 关于发布《罕见疾病药物临床研发技术指导原则》的通告[EB/OL]. (2021-12-31)[2022-01-05]. https://www.cde.org.cn/main/news/viewInfoCommon/c4e1ef312a0a0c039a7a4ca55b91d4e8.
    [12] Baranello G, Darras BT, Day JW, et al. Risdiplam in Type 1 Spinal Muscular Atrophy[J]. N Engl J Med, 2021, 384: 915-923.
    [13] Darras BT, Masson R, Mazurkiewicz-Bełdzińska M, et al. Risdiplam-Treated Infants with Type 1 Spinal Muscular Atrophy versus Historical Controls[J]. N Engl J Med, 2021, 385: 427-435.
    [14] Qi Y, Mckeever K, Taylor J, et al. Pharmacokinetic and Pharmacodynamic Modeling to Optimize the Dose of Vestronidase Alfa, an Enzyme Replacement Therapy for Treatment of Patients with Mucopolysaccharidosis Type Ⅶ: Results from Three Trials[J]. Clin Pharmacokinet, 2019, 58: 673-683.
    [15] Wang RY, da Silva Franco JF, López-Valdez J, et al. The long-term safety and efficacy of vestronidase alfa, rhGUS enzyme replacement therapy, in subjects with mucopolysaccharidosis Ⅶ[J]. Mol Genet Metab, 2020, 129: 219-227.
    • Relative Articles(0)
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(2)  / Tables(4)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (506) PDF downloads(60) Cited by()
    Proportional views
    Related
    Links: National Health Commission of the People's Republic of China Chinese Academy of Medical Sciences(CAMS) AMLC Check CNKI Database CNKI Term Online Chinese General Practice
    Address：Room 302,Third Floor,Building 7, No. 1 Shuaifuyuan, Wangfujing, Dongcheng District, Beijing 100730, China
    Tel：010-69154261/4262
    E - mail：medj@pumch.cn
    mjpumch@126.com
    Copyright of website：Editorial Office of Medical Journal of Peking Union Medical College Hospital

    Supported by: Beijing Renhe Information Technology Co. Ltd    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return